For the Inventor, By the Inventor

Enter assignee name

Foster City, CA, United States of America

Forty Seven, Inc.

Calculating rank

USPTO Granted Patents = 15

EPO Patents = 11

Trademarks = 2

Forward Citations = 20

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Jie Liu (9 out of 40 patents)

Jens-Peter Volkmer (8 out of 30 patents)

Mark P Chao (6 out of 23 patents)

4. Ravindra Majeti (4 out of 45 patents)

5. Irving L Weissman (4 out of 149 patents)

6. Klaus Heinrich Schwamborn (3 out of 9 patents)

7. Nicola Beltraminelli (3 out of 6 patents)

8. Pierre Garrone (3 out of 11 patents)

9. Kavitha Sompalli (3 out of 3 patents)

10. Mehdi Lahmar (3 out of 3 patents)

11. Stéphanie Fallot (3 out of 3 patents)

12. Marie Châlons-Cottavoz (3 out of 3 patents)

13. Chris Hidemi Mizufune Takimoto (3 out of 3 patents)

14. Aaron Michael Ring (1 out of 35 patents)

15. Yinuo Cao (1 out of 1 patent)

15 patents: Sort by Forward Citations

1. 12274746 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2025-04-14),

2. 12194093 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2025-01-14),

3. 12091458 - Humanized antibodies against c-Kit (2024-09-17),

4. 12060423 - Humanized, mouse or chimeric anti-CD47 monoclonal antibodies (2024-08-13),

5. 11891450 - Anti-CD47 agent-based treatment of CD20-positive cancer (2024-02-06),

6. 11802153 - Anti-CD47 agent-based ovarian cancer therapy (2023-10-31),

7. 11795223 - Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia (2023-10-24),

8. 11753480 - Anti-SIRP-alpha antibodies and related methods (2023-09-12),

9. 11643461 - Humanized, mouse or chimeric anti-CD47 monoclonal antibodies (2023-05-09),

10. 11208482 - Humanized antibodies against c-Kit (2021-12-28),

11. 11141480 - Dosing parameters for CD47 targeting therapies to hematologic malignancies (2021-10-12),

12. 11041022 - Humanized antibodies against c-Kit (2021-06-22),

13. 10961318 - Anti-SIRP-α antibodies and related methods (2021-03-30),

14. 10927173 - Humanized, mouse or chimeric anti-CD47 monoclonal antibodies (2021-02-23),

15. 10611842 - Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy (2020-04-07),

Company Overview

Forty Seven, Inc. is a biotechnology company based in Foster City, California, focused on developing innovative immunotherapies for cancer treatment. The company specializes in harnessing the power of the immune system to target and eliminate cancer cells, with a strong emphasis on monoclonal antibodies and other therapeutic modalities. By leveraging cutting-edge research and technology, Forty Seven aims to improve patient outcomes and advance the field of oncology, contributing to the broader landscape of cancer therapeutics.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Nov 3 2026

15 Patents

#32 in Foster City, CA

#5,045 in California

#21,100 in US

#40,018 in the World

Foster City, CA, United States of America

Forty Seven, Inc.

Forward Citations = 20

17 inventors:

Jie Liu (9 out of 40 patents)

Jens-Peter Volkmer (8 out of 30 patents)

Mark P Chao (6 out of 23 patents)

4. Ravindra Majeti (4 out of 45 patents)

5. Irving L Weissman (4 out of 149 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Forty Seven, Inc.. Retrieved from https://idiyas.com/company/forty-seven

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…